Raymond James Maintains Outperform on PTC Therapeutics, Lowers Price Target to $55
Portfolio Pulse from richadhand@benzinga.com
Raymond James analyst Danielle Brill has maintained an 'Outperform' rating on PTC Therapeutics (NASDAQ:PTCT), but lowered the price target from $58 to $55.

August 04, 2023 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
PTC Therapeutics' price target has been lowered from $58 to $55 by Raymond James, though the 'Outperform' rating is maintained.
The lowering of the price target by Raymond James could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100